Skip to main content

Advertisement

SpringerLink
Log in

Hypertensive cardiovascular disease in African Americans

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension is the most common public health challenge in the United States because of its prevalence and associated increase in comorbid cardiovascular diseases [1]. Yearly expenses related directly or indirectly to the treatment and detection of hypertension in the United States are approximately $10 billion, excluding the enormous yearly financial burden of $259 billion and the social burden from heart disease and stroke, which remain the first and third leading causes of death, respectively, in the United States [2]. Despite the importance of these observations, blood pressure is poorly controlled in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Dustan HP, Roccella EJ, Garrison HH: Controlling hypertension: a research success story. Arch Intern Med 1996, 156:1926–1935.

    Article  PubMed  CAS  Google Scholar 

  2. National Institutes of Health, National Heart, Lung, and Blood Institute: Morbidity and mortality 1996: chartbook on cardiovascular, lung, and blood diseases: data points document. Bethesda: National Institutes of Health; 1996.

    Google Scholar 

  3. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413–2446. Using evidence-based medicine and consensus this report describes the national guidelines for hypertension control with a special emphasis on risk stratification in patients with hypertension. It also provides evidence for the use of combination of antihypertensive medications for hypertension control in the high risk groups.

  4. Kaplan NM: Ethnic aspects of hypertension. Lancet 1994, 344:45–52.

    Google Scholar 

  5. Cooper R, Rotimi C: Hypertension in populations of West African origins: is there a genetic predisposition? J Hypertens 1994, 12:215–227.

    Article  PubMed  CAS  Google Scholar 

  6. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension on the adult US population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25:305–313.

    PubMed  CAS  Google Scholar 

  7. Berlowitz DR, Ash AS, Hickey EC, et al.: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339:1957–1963. This is on of the few studies in hypertension in which process of care for single visit was examined in detail. The study demonstrates that physician’s awareness is an important determinant of optimal bloo pressure control.

    Article  PubMed  CAS  Google Scholar 

  8. O’Donnell CJ, Kannel WB: Is there a racial predisposition to hypertension? Hypertension 1998, 32:817–819. This is a comprehensive editorial about polygenic etiology of hypertension in African Americans.

    PubMed  Google Scholar 

  9. Weinberger MH: More spice on the salt debate. Arch Intern Med 1997, 157:2407–2408.

    Article  PubMed  CAS  Google Scholar 

  10. Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 1996, 27:481–490.

    PubMed  CAS  Google Scholar 

  11. Intersalt Cooperative Research Group: Intersalt: and international study of electrolyte excretion and blood pressure. BMJ 1988, 297:319–328.

    Article  Google Scholar 

  12. Midgley JP, Matthew AG, Greenwood CMT, Logan AG: Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996, 275:1590–1597.

    Article  PubMed  CAS  Google Scholar 

  13. Cutler JA, Foreman D, Elliocott P, Suh I: An overview of randomized trials of sodium reduction and blood pressure. Hypertension 1996, 17(suppl 1):127–133.

    Google Scholar 

  14. Weir MR, Dengel DR, Behrens MT, Goldberg AP: Salt-induces increase in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995, 25:1339–1344.

    PubMed  CAS  Google Scholar 

  15. Campese VM, Parise M, Karubian F, et al.: Abnormal renal hemodynamcis in black salt-sensitive patients with hypertension. Hypertension 1991, 18:805–812.

    PubMed  CAS  Google Scholar 

  16. Cooper R, Aina O, Chaco L: Cell cation and blood pressure in US whites, US blacks, and West African blacks. J Hum Hypertens 1990, 4:477–484.

    PubMed  CAS  Google Scholar 

  17. Chrysant SG, Danisa K, Kem DC, et al.: Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1979, 1:136–141.

    PubMed  CAS  Google Scholar 

  18. Zinner SH, Margolius HS, Rosner B, et al.: Familial aggregation of urinary kallikrein concentration in childhood: relation of blood pressure, race and urinary electrolytes. Am J Epidemiol 1976, 104:124–132.

    PubMed  CAS  Google Scholar 

  19. Levy SB, Lilley JJ, Frigon RP, et al.: Urinary kallikrein and plasma renin activity as determinants of renal blood flow: the influence of race and dietary sodium intake. J Clin Invest 1977, 60:129–138.

    Article  PubMed  CAS  Google Scholar 

  20. Anderson NB, Lane JD, Monou H, et al.: Racial differences in cardiovascular reactivity to mental arithmetic. Int J Psychophysiol 1988, 6:161–164.

    Article  PubMed  CAS  Google Scholar 

  21. Frohlich ED, Messerli FH, Dunn FG, et al.: Greater renal vascular involvement in the black patient with essential hypertension: a comparison of systematic and renal hemodynamic in blacks and white patients. Miner Electrolyte Metab 1996, 1984:173–177.

    Google Scholar 

  22. Weir MR, Tuck ML: Essential hypertension in blacks: it is a metabolic disorder ? Am J Kidney Dis 1993, 21:58–67.

    PubMed  CAS  Google Scholar 

  23. He J, Klag MJ, Caballero B, et al.: Plasma insulin level and incidence of hypertension in African-Americans and whites. Arch Intern Med 1999, 159:498–503. A prospective study of 377 subjects (140 African Americans and 237 whites) from the cohort of 463 subjects initially enrolled for TOHP-I and followed for 7.1 years. This study demonstrates the effect of baseline insulin levels and insulin-to-glucose ratio on blood pressure in African Americans.

    Article  PubMed  CAS  Google Scholar 

  24. Kaufman JS, Durazo-Avizu RA, Rotimi CN, et al.: Obesity and hypertension prevalence in populations of African origin: results from the International Collaborative Study on Hypertension in Blacks. Epidemiology 1996, 7:398–405.

    Article  PubMed  CAS  Google Scholar 

  25. Beaglehole T, Tyroler HA, Cassel JC, et al.: An epidemiological study of left ventricular hypertrophy in the biracial population of Evans County, Georgia. J Chron Dis 1975, 28:549–559.

    Article  PubMed  CAS  Google Scholar 

  26. Taylor JO, Borhani NO, Entwisle G, et al.: Hypertension Detection and Follow-up Program Cooperative Group: summary of the baseline characteristics of the hypertensive participants. Hypertension 1983, 5:44–50.

    Google Scholar 

  27. Savage DD, Henry WL, Mitchell JR, et al.: Echocardiographic comparison of black and white hypertensive subjects J Natl Med Assoc 1979, 71:709–712.

    PubMed  CAS  Google Scholar 

  28. Levy D, Anderson KM, Savage DD, et al.: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Study. Ann Intern Med 1988, 108:7–13.

    PubMed  CAS  Google Scholar 

  29. Gardin JM, Wagenknecht LE, Anton-Culver H, et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Circulation 1995, 92:380–387.

    PubMed  CAS  Google Scholar 

  30. Arnett DK, Rautaharju P, Crow R, et al.: Black-white differences in electrocardiographic left ventricular mass and its association with blood pressure (the ARIC Study). Am J Cardiol 1994, 74:247–252.

    Article  PubMed  CAS  Google Scholar 

  31. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.

    Article  PubMed  CAS  Google Scholar 

  32. Liao Y, Cooper RS, McGee DL, et al.: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995, 273:1592–1597.

    Article  PubMed  CAS  Google Scholar 

  33. Liao Y, Cooper RS, Durazo-Arvizu R, et al.: Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997, 29:641.

    Article  PubMed  CAS  Google Scholar 

  34. Pringle SD, Dunn FG, Macfarlan PW, et al.: Significance of ventricular arrhythmias in systematic hypertensive patients with left ventricular hypertrophy. Am J Cardiol 1992, 69:913–917.

    Article  PubMed  CAS  Google Scholar 

  35. The Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985, 7:105–112.

    Google Scholar 

  36. Frohlich ED, Epstein C, Chbanian AV, et al.: The heart in hypertension. N Engl J Med 1992, 74:247–252.

    Google Scholar 

  37. Mosterd A, D’Agostino RB, Silbershatz H, et al.: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999, 340:1221–1227. [Editorial comment on page 1279–1280.] The authors describe the follow-up of 50 years in the Framingham Heart Study Cohort with longitudinal electrocardiographic data, and importance of blood pressure reduction and regression of left ventricular hypertrophy regardless of the type of antihypertensive medication used to control the blood pressure.

    Article  PubMed  CAS  Google Scholar 

  38. Caplan LR: Strokes in African-Americans. Circulation 1991, 83:1469–1471.

    PubMed  CAS  Google Scholar 

  39. Fisher CM: Clinical syndromes in cerebral thrombosis, hypertensive hemorrhage and ruptured saccular aneurysm. Clin Neurosurg 1975, 22:117–129.

    PubMed  CAS  Google Scholar 

  40. Rosamond WD, Folsom AR, Chambless LE, et al.: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the atherosclerosis risk in communities (ARIC) cohort. Stroke 1999, 30:736–743. This is a 7.2 years follow-up study of 15792 in four US communities and revealed nearly 40% higher incidence of ischemic strokes in African Americans compared with whites.

    PubMed  CAS  Google Scholar 

  41. Zampaglione B, Pascale C, Marchismo M, Cavallo-Perin P: Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996, 27:114–147.

    Google Scholar 

  42. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data Systems 1991 Annual Report. Bethesda: 1991, 13–20: A1–A22.

  43. Powers RD, Wallin JD: End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med 1998, 158:793–800. This is a in depth review of various risk factors in African American and Native Americans, two high risk groups for the development of hypertension and hypertension related renal failure and risk of progression to end-stage renal disease.

    Article  PubMed  CAS  Google Scholar 

  44. Feldman HI, Klag MJ, Chiapella AP, Whelton PK: End-stage renal disease in US minority groups. Am J Kidney Dis 1992, 19:397–410.

    PubMed  CAS  Google Scholar 

  45. Walker WG, Neaton JD, Cutler JA, et al.: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA 1992, 268:3085–3091.

    Article  PubMed  CAS  Google Scholar 

  46. Shulman ND, Ford CE, Hall WD, et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension 1989, 13:180–193.

    Google Scholar 

  47. Rostand SG, Brown G, Kirk KA, et al.: Renal insufficiency in treated essential hypertension. N Engl J Med 1989, 320:684–688.

    Article  PubMed  CAS  Google Scholar 

  48. Frohlich ED, Messerli FH, Dunn FG, et al.: Greater renal vascular involvement in the black patient with essential hypertension: a comparison of systemic and renal hemodynamics in black and white patients Miner Electrolyte Metab 1984, 10:173–177.

    PubMed  CAS  Google Scholar 

  49. Levy SB, Talner LB, Coel MR, et al.: Renal vasculature in essential hypertension: Racial differences. Ann Intern Med 1978, 88:12–16.

    PubMed  CAS  Google Scholar 

  50. Pitcock JA, Johnson JG, Hatch FE, et al.: Malignant hypertension in blacks. Malignant intrarenal arterial disease as observed by light and electron microscopy. Hum Pathol 1976, 7:333–346.

    Article  PubMed  CAS  Google Scholar 

  51. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 1989, 35:670–674.

    Article  PubMed  CAS  Google Scholar 

  52. Perneger TV, Whelton PK, Klag MJ, et al.: Diagnosis of hypertensives end-stage renal disease: effect of patient’s race. Am J Epidemiol 1995, 141:10–15.

    PubMed  CAS  Google Scholar 

  53. Wright JT Jr, Kirk KA, Kusek JW, et al.: Design of the African-American study of Kidney Disease and Hypertension (AASK) pilot study. Control Clin Trials 1996, 17:3S-16S.

    Article  PubMed  Google Scholar 

  54. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension vascular disease, and nephropathy: an update. Hypertension 1997, 26:869–874.

    Google Scholar 

  55. National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994, 43:145–151.

    Google Scholar 

  56. Hypertension in Diabetes Study Group: HDS 2: increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993, 11:319–325.

    Article  Google Scholar 

  57. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356–361.

    Article  PubMed  CAS  Google Scholar 

  58. Kaplan NM: The deadly quartet: upper body obesity, glucos intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989, 149:1514–1521.

    Article  PubMed  CAS  Google Scholar 

  59. Krop JS, Coresh J, Chambless LE, et al.: A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: the atherosclerosis risk in communities studies. Arch Intern Med 1999, 159:1777–1783. This prospective study demonstrates that early and faster decline in diabetic African Americans is secondary to potentially modifiable factors with more than 80% reduction in excess risk after adjusting for the risk factors.

    Article  PubMed  CAS  Google Scholar 

  60. Kasiske BL, Kalil RSN, Ma JZ, et al.: Effects of antihyertensive therapy on the kidney in patients with diabetes: a meta-regression analysis Ann Intern Med 1993, 118:129–138.

    PubMed  CAS  Google Scholar 

  61. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:705–713. UKPDS 38 is the muticenter, randomised, controlled study with 9 years follow-up of 1148 hypertensive patients with type 2 diabetes mellitus. This study demonstrates that effective control of blood pressure decreases proteinuria and slows the progression in renal failure.

    Google Scholar 

  62. Ooi WL, Budner NS, Cohen H, et al.: Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension 1989, 14:227–234.

    PubMed  CAS  Google Scholar 

  63. Materson BJ, Reda DJ, Cushman WC, et al.: Single-rug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328:914–921.

    Article  PubMed  CAS  Google Scholar 

  64. Weir MR, Chrysant SG, McCarron DA, et al.: Influence of a race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998, 31:1088–1096. This clinical study describes the influence of low- and high-salt diet on the antihypertensive effects of isradipine (calcium channel blocker) and enalapril (angiotensin converting enzyme blocker) in three ethnic groups (blacks, hispanics and whites) with hypertension.

    PubMed  CAS  Google Scholar 

  65. Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997, 227:739–745.

    Article  Google Scholar 

  66. Gottdiener JS, Reda DJ, Materson BJ, et al.: Importance of obesity, race and age to the cardiac structural and functional effects of hypertension: The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. J Am Coll Cardiol 1994, 24:1492–1498.

    Article  PubMed  CAS  Google Scholar 

  67. Saunder E, Curry C, Hinds J, et al.: Labetolol compared to propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987, 3:294–302.

    Google Scholar 

  68. Luther RR, Klepper MJ, Maurath CJ, et al.: Efficacy of terazosin in the treatment of essential hypertension in blacks. J Hum Hypertens 1990, 4:151–153.

    PubMed  CAS  Google Scholar 

  69. Williams GH: Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988, 319:1517–1525.

    Article  PubMed  CAS  Google Scholar 

  70. The SOLVD Investigator: Effect of enalapril on survival on patients with reduces left ventricular ejection fractions and chronic congestive heart failure. N Engl J Med 1991, 325:293–302.

    Article  Google Scholar 

  71. Weir MR, Gray JM, Paster R, et al.: Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995, 26:124–130.

    PubMed  CAS  Google Scholar 

  72. Weir MR, Saunders E: Racial similarity in response to the angiotensin converting enzyme inhibitors trandolapril. Am J Hypertens 1996, 9:174–179.

    Article  Google Scholar 

  73. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensinogen — converting enzyme inhibitors therapy: a review of the literature and pathophysiology. Ann Intern Med 1992, 117:234–242.

    PubMed  CAS  Google Scholar 

  74. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649–1654.

    Article  PubMed  CAS  Google Scholar 

  75. Hall WD, Reed JW, Flack JM, et al.: Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. Arch Intern Med 1998, 158:2029–2034. This is a randomized, double-blind study reporting equal efficacy and safety of three commonly prescribed calcium-channel blockers (amlodipine besylate, nifedipine coat core, and nifedipine gastrointestinal therapeutics (GITS) in the African-American population with hypertension.

    Article  PubMed  CAS  Google Scholar 

  76. Weir R, Hall P, Behrens T, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997, 30[part 1]:422–427.

    PubMed  CAS  Google Scholar 

  77. Appel LJ, Moore TJ, Obarzanek E, et al., for the DASH Collaborative Research Group: A clinical trial of the effects o dietary patterns on blood pressure. N Engl J Med 1997, 336:1117–1124.

    Article  PubMed  CAS  Google Scholar 

  78. Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med 1997, 157:657–667.

    Article  Google Scholar 

  79. Puddey IB, Parker M, Beilen LJ, et al.: Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992, 20:533–541.

    PubMed  CAS  Google Scholar 

  80. Kokkinos PF, Narayakn P, Collerman JA, et al.: Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med 1995, 333:1462–1467.

    Article  PubMed  CAS  Google Scholar 

  81. Agency for Health Care Policy and Research. You Can Quit Smoking: Consumer Guide. Washington, DC: US Dept of Health and Human Services; 1996. AHCPR publication 96-0695.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology N3W143, University of Maryland Hospital, 22 S. Greene Street, 21201, Baltimore, MD, USA

    Ravinder K. Wali MD & Matthew R. Weir MD

Authors
  1. Ravinder K. Wali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew R. Weir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wali, R.K., Weir, M.R. Hypertensive cardiovascular disease in African Americans. Curr Hypertens Rep 1, 521–528 (1999). https://doi.org/10.1007/s11906-996-0025-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-996-0025-8

Keywords

Search

Navigation